Fundraising Fox
/Companies
Sign in

Neuron23

South San Francisco, US · Founded 2018 · 29 employees on LinkedIn · 12 known investors

Find your way into Neuron23

Sign up to see every warm intro you have to Neuron23

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Neuron23 team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

Neuron23 is a biotech company using data science, human genetics, and functional genomics to develop precision medicines and companion diagnostics for neurodegenerative diseases, starting with an LRRK2 program for Parkinson's disease. It aims to match patient subsets defined by genetic drivers with targeted therapies for conditions such as Parkinson's and Alzheimer's.

AI & Machine LearningBiotechDeep TechDigital Health

Founders & leadership

NSNancy Stagliano
Nancy StaglianoChief Executive Officer and Chair of the Board

Investors · 12

HBM Partnerslisted by HBM PartnersZug · $5M – $50M

How we know: HBM Partners's portfolio page · worldpharmaceuticals.net · Not right? Tell us

Kleiner Perkinslisted by Kleiner PerkinsMenlo Park · $500K – $15M

How we know: Kleiner Perkins's portfolio page · a partner's Signal profile · worldpharmaceuticals.net · Not right? Tell us

SoftBank Grouplisted by SoftBank GroupTokyo

How we know: SoftBank Group's portfolio page · Not right? Tell us

SoftBank Vision Fundlisted by SoftBank Vision FundLondon

How we know: funding news · Not right? Tell us

Westlake Village BioPartnerslisted by Westlake Village BioPartnersLos Angeles · $100K – $5M

How we know: Westlake Village BioPartners's portfolio page · funding news · worldpharmaceuticals.net · Not right? Tell us

ACORN BIOVENTURESreportedNew York

How we know: worldpharmaceuticals.net · Not right? Tell us

Cowen Healthcare InvestmentsreportedNew York

How we know: worldpharmaceuticals.net · Not right? Tell us

REDMILEreportedSan Francisco

How we know: worldpharmaceuticals.net · Not right? Tell us

Also in the syndicate · 3

Perceptive AdvisorsSoftBank Vision Fund 2leadSurveyor Capital

Funding

SEC filings, press & company announcements

Source: company announcements and press reports — follow each round's link for the claim.

In the news

Neuron23 Raises $96.5M in Series D Financingfinsmes.com · Jun 2025Neuron23 Announces $96.5 Million Series D Financing and First Patient Dosed in Global Phase 2 NEULARK Clinical Trial of NEU-411 for Early Parkinson’s Disease - BioSpacebiospace.com · Jun 2025Neuron23 Closes $100 Million Series C Financing Round, Nominates Clinical Candidate for Parkinson's Diseaseprnewswire.com · Mar 2022

Frequently asked questions

What does Neuron23 do?
Neuron23 is a biotech company using data science, human genetics, and functional genomics to develop precision medicines and companion diagnostics for neurodegenerative diseases, starting with an LRRK2 program for Parkinson's disease. It aims to match patient subsets defined by genetic drivers with targeted therapies for conditions such as Parkinson's and Alzheimer's.
Who are Neuron23's investors?
Neuron23's investors include HBM Healthcare Investments, HBM Partners, Kleiner Perkins, SoftBank Group, SoftBank Vision Fund, Westlake Village BioPartners, ACORN BIOVENTURES, Cowen Healthcare Investments and 1 more.
Where is Neuron23 headquartered?
Neuron23 is headquartered in South San Francisco, US.